Meeting
2023 ASCO Annual Meeting
Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).
Authors
John Yohan Rhee
Massachusetts General Hospital, Boston, MA
John Yohan Rhee , Kun Wei Song , Isabel Arrillaga-Romany , Deborah Anne Forst , Justin T. Jordan , Ina Ly , Scott Randall Plotkin , Nancy Wang , Michael Parsons , Elizabeth R Gerstner , Jorg Dietrich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2065)
DOI
10.1200/JCO.2023.41.16_suppl.2065
Abstract #
2065
Poster Bd #
422
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
First Author: Claud Grigg
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2023 ASCO Annual Meeting
Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).
First Author: Matthaios Kapiris
Poster
2023 ASCO Annual Meeting
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
First Author: Alexandra Leary